(AOF) – The Spineway Group announces the recent 510(k) clearance from the United States Food and Drug Administration (FDA) for its VEO posterior spinal fixation system. The specialist in innovative implants for the treatment of severe spinal pathologies (spine), specifies that this authorization, which allows the Group to market its VEOS system in the United States, “reinforces its strategic approach aimed at developing its activities in the American market.
The VEOS posterior spinal fixation system is intended to be “easy to use, fully modular”: it allows surgeons to perform interventions “in an open, minimally invasive and percutaneous (MIS) approach” for the treatment of a wide range of pathologies spinal, from degenerative spine to complex surgery and deformities.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
This is a Smartvoice article: see legal notices